BORYUNG CORPORATION |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,930 KRW | -0.18% |
|
-1.09% | -8.07% |
| Sales 2024 * | 1,050B 764M | Sales 2025 * | 1,137B 827M | Capitalization | 726B 528M |
|---|---|---|---|---|---|
| Net income 2024 * | 66B 47.98M | Net income 2025 * | 79B 57.43M | EV / Sales 2024 * | 0.79 x |
| Net Debt 2024 * | 106B 77.43M | Net Debt 2025 * | 38.6B 28.06M | EV / Sales 2025 * | 0.67 x |
| P/E ratio 2024 * |
11.4
x | P/E ratio 2025 * |
9.44
x | Employees | 1,403 |
| Yield 2024 * |
0.91% | Yield 2025 * |
0.91% | Free-Float | 40.49% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.18% | ||
| 1 week | -1.09% | ||
| Current month | -15.53% | ||
| 1 month | -18.86% | ||
| 3 months | -13.05% | ||
| 6 months | +19.32% | ||
| Current year | -8.07% |
1 week
10 820.00
11 250.00
1 month
10 800.0013 360.00
Current year
10 800.0013 750.00
1 year
7 440.0013 750.00
3 years
7 440.0023 541.66
5 years
6 365.0625 083.33
10 years
4 675.5325 083.33
| Managers | Title | Age | Since |
|---|---|---|---|
Jung Gyun Kim
CEO | Chief Executive Officer | - | 21-12-31 |
Jae-Sool Lee
AUD | Comptroller/Controller/Auditor | 65 | - |
Sang-Bae Yoon
SAM | Sales & Marketing | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yoon-Sik Park
BRD | Director/Board Member | 54 | 19-03-21 |
Gwang-Sup Gil
BRD | Director/Board Member | 76 | 13-03-14 |
In-Goo Jeon
BRD | Director/Board Member | 72 | 19-03-21 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10,930 | -0.18% | 105,144 |
| 24-04-25 | 10,950 | +0.37% | 153,482 |
| 24-04-24 | 10,910 | -1.80% | 241,017 |
| 24-04-23 | 11,110 | -0.09% | 103,410 |
| 24-04-22 | 11,120 | +0.63% | 141,087 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Boryung Corp, formerly Boryung Pharm Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company mainly manufactures and distributes pharmaceutical products including antihypertensive drugs, gastrointestinal disorder drugs, antibiotics, gastric ulcer drugs, oral antibiotics, anticancer drugs and antihyperlipidemic drugs, among others. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
10,930
KRW
Average target price
15,333
KRW
Spread / Average Target
+40.29%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.07% | 529M | |
| +19.62% | 43.78B | |
| +20.44% | 21.89B | |
| +10.86% | 14.45B | |
| +13.07% | 13.63B | |
| +37.46% | 11.49B | |
| -8.59% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.06B |
- Stock Market
- Equities
- A003850 Stock
